CEFEPIME HYDROCHLORIDE pharmaceutical API fine chemical suppliers

Subscribe to access the full database, or Get Started Free
Vendor	Vendor Homepage	Vendor Sku	API Url
NovoSeek	⤷ Get Started Free	9571075	⤷ Get Started Free
Hangzhou APIChem Technology	⤷ Get Started Free	AC-6021	⤷ Get Started Free
ABI Chem	⤷ Get Started Free	AC1L1E3B	⤷ Get Started Free
>Vendor	>Vendor Homepage	>Vendor Sku	>API Url

Last updated: July 28, 2025

Introduction

CEFEPIME hydrochloride, a fourth-generation cephalosporin antibiotic, is widely used in the treatment of complex bacterial infections, including pneumonia, urinary tract infections, and skin infections. Its efficacy relies heavily on the supply chain of high-quality bulk Active Pharmaceutical Ingredients (APIs). As the pharmaceutical industry seeks reliable sources for CEFEPIME hydrochloride, understanding the global landscape of API manufacturing is critical for strategic procurement, risk mitigation, and ensuring pharmaceutical quality standards.

Global API Manufacturing Landscape for CEFEPIME Hydrochloride

Major API Production Countries

The production of CEFEPIME hydrochloride APIs predominantly occurs in regions with established pharmaceutical manufacturing infrastructure, notably India, China, and certain European countries.

India:
India’s pharmaceutical sector is a global API hub, leveraging cost advantages, व्यापक manufacturing capacity, and regulatory expertise. Leading Indian API manufacturers such as Sun Pharmaceutical Industries, Aurobindo Pharma, Cadila Healthcare, and Hetero Labs produce cefepime hydrochloride at scale. These firms often integrate API production with finished drug manufacturing, ensuring supply chain control.

China:
China's pharmaceutical industry has expanded significantly, providing cost-effective APIs with rapidly evolving quality standards. Key Chinese manufacturers such as Shandong Xinhua Pharmaceutical and Qingdao BGI Pharmaceutical supply cefepime hydrochloride, often exporting to global markets.

Europe:
European API suppliers, primarily in Germany, Italy, and Switzerland, focus on high-quality, cGMP-compliant APIs, catering to markets with strict regulatory standards. Companies like Rottapharm Biotech and Lonza offer cefepime hydrochloride APIs, often at premium pricing but with robust quality assurance.

Leading API Suppliers and Manufacturers

Indian API Manufacturers

Aurobindo Pharma:
A major player with WHO-GMP certification, providing cefepime hydrochloride APIs globally. Their scale and adherence to international standards make them a preferred choice.
Hetero Labs:
Offers cefepime API as part of their broad-spectrum cephalosporin portfolio, emphasizing quality and supply chain reliability.
Zydus Cadila:
Specializes in injectable APIs, with cefepime hydrochloride included in their sterile API manufacturing portfolio.
Biological E. Limited:
Export-oriented manufacturer with global certifications, focusing on cGMP-compliant cefepime APIs.

Chinese API Manufacturers

Shandong Xinhua Pharmaceutical:
Known for cost-effective APIs, with capacity for large-scale cefepime hydrochloride production, compliant with Chinese GMP standards.
Qingdao BGI Pharmaceutical:
Provides cefepime API for export markets, accredited with Chinese GMP and ISO certifications.
Shenzhen Kangtai Pharmaceutical:
An emerging supplier integrating API production with finished drugs; known for competitive pricing.

European and US API Suppliers

Rottapharm Biotech (Italy):
Specializes in high-quality cephalosporin APIs, adhering to stringent European regulations.
Lonza (Switzerland):
Global leader focusing on premium quality APIs with comprehensive regulatory approval support, including for cefepime hydrochloride.
Fresenius Kabi (Germany):
Offers sterile APIs with certifications conforming to both EU and US standards, suitable for critical care formulations.

Regulatory Considerations and Certifications

Ensuring the quality of cefepime hydrochloride APIs hinges on manufacturers’ compliance with Good Manufacturing Practice (GMP), ISO standards, and pharmacopoeial specifications. Suppliers should demonstrate:

GMP Certification:
Mandatory for global acceptance, especially for APIs intended for injection.
ISO Certification:
Ensures consistency in manufacturing processes and quality management.
Certifications for International Markets:
USFDA approval or EDQM certification facilitate entry into highly regulated markets.

Selecting suppliers with a proven compliance record reduces supply risk and eases regulatory approval processes.

Supply Chain Dynamics and challenges

The supply chain for CEFEPIME hydrochloride APIs faces several challenges:

Regulatory Variability:
Differences in quality standards and regulatory requirements across regions can impact sourcing decisions.
Pricing Fluctuations:
Cost differences between Indian, Chinese, and European manufacturers influence procurement strategies.
Quality Assurance Risks:
Higher quality assurance standards require due diligence; subpar APIs may lead to batch rejections or regulatory sanctions.
Supply Reliability:
Manufacturing disruptions caused by geopolitical issues, raw material shortages, or pandemic impacts can hamper supply continuity.

To mitigate these risks, pharmaceutical companies typically diversify suppliers, adopt long-term supply agreements, and prioritize GMP-certified, recognized manufacturers.

Emerging Trends and Future Outlook

Shift Towards Quality and Compliance:
Regulatory bodies like FDA and EMA increasingly scrutinize API manufacturing practices, pushing manufacturers toward higher standards.
Local API Production Initiatives:
Some countries are investing to localize API manufacturing, reducing dependency on imports and enhancing supply security.
Technological Innovations:
Advances in biocatalysis and green chemistry are refining cefepime synthesis, potentially reducing costs and environmental impact.
Certification and Audits:
Third-party audits and supplier pre-qualification processes are becoming vital to validate API quality and manufacturing capacity.

Conclusion

The global landscape of cefepime hydrochloride API supply is characterized by key manufacturing hubs, with India and China dominating in scale and cost-effectiveness, and Europe emphasizing quality standards. Pharmaceutical companies must navigate regulatory requirements, quality assurance protocols, and supply chain risks when sourcing APIs. Ensuring supplier compliance with GMP, ISO, and other certifications is critical for maintaining product integrity and market access. Strategic diversification and long-term partnerships with reliable, certified manufacturers underpin supply security for this vital antibiotic.

Key Takeaways

India and China remain dominant API suppliers for cefepime hydrochloride, offering cost advantages but requiring rigorous quality vetting.
European suppliers prioritize high-quality standards, suitable for markets with strict regulatory environments.
Compliance with GMP, ISO, and certifications like USFDA or EDQM are essential for ensuring API quality and regulatory acceptance.
Supply chain resilience depends on supplier diversification, long-term agreements, and proactive regulatory engagement.
Emerging trends include technological innovations and local manufacturing to enhance supply security and sustainability.

FAQs

1. What are the primary factors to consider when sourcing cefepime hydrochloride API?
Quality certifications (GMP, ISO), regulatory compliance, supply reliability, production capacity, and cost-effectiveness.

2. Are Chinese API manufacturers as reliable as Indian or European counterparts?
Many Chinese manufacturers meet international standards and supply globally; due diligence and certification verification are essential.

3. How does regulatory compliance impact API sourcing decisions?
Regulatory compliance ensures market acceptance, minimizes approval delays, and guarantees product safety and efficacy.

4. What role does certification play in API quality assurance?
Certifications like GMP, ISO, and regional approvals (USFDA, EDQM) validate manufacturing quality and facilitate regulatory approval processes.

5. How are emerging trends shaping the future of cefepime hydrochloride API sourcing?
Focus on higher standards, technological advances, local manufacturing, and supply chain resilience to meet global demand sustainably.

Sources:

[1] Pharmaceutical Technology. Global API Market Dynamics.
[2] IMS Health (IQVIA). Regional API Manufacturing Trends.
[3] WHO International Pharmacopoeia. Standards for Cephalosporin APIs.
[4] USFDA and EMA Regulatory Guidelines for API Manufacturing.
[5] Industry Reports on Chinese and Indian API Manufacturers.

Bulk Pharmaceutical API Sources for CEFEPIME HYDROCHLORIDE